Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Mycosis Fungoides 2Neoplasms 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Amines × Clear all
NCT06149247 2025-08-20

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Soligenix

Phase 2 Completed
10 enrolled 7 charts
Lymphoid

Mycosis Fungoides

NCT02296164 2020-03-04

PROVe

Helsinn Therapeutics (U.S.), Inc

Completed
300 enrolled 7 charts
DermatologicLymphoid

Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡